Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy

Smith, Peter A.; Heimer, Gun; Lindskog, Marianne; Ulmsten, Ulf

doi:10.1016/0378-5122(93)90059-q

Cited by 117 publications

(52 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More and more studies are being com pleted showing that very low dose estrogen therapies are highly effective against the char acteristic vaginal symptoms of urogenital age ing such as dryness, itch, burning and pain on intercourse [13]. They also have the advanTreatment tage over conventional HRT that there is no endometrial proliferation.…”

Section: Estrogen Receptorsmentioning

confidence: 99%

Low-Dose Estrogen in Urogenital Ageing

Heimer

1994

Gerontology

Self Cite

View full text Add to dashboard Cite

Section: Estrogen Receptorsmentioning

confidence: 99%

Low-Dose Estrogen in Urogenital Ageing

Heimer

1994

Gerontology

Self Cite

View full text Add to dashboard Cite

“…Estring is inserted into the upper vagina where it remains for up to 3 months while releasing 5-10 g per day of estradiol. Estring and Vagifem have demonstrated an approximate 90% improvement in relief of the symptoms of atrophic vaginitis: vaginal dryness, itching, and discharge [48,50,51]. Both agents have been shown to dramatically reduce the frequency of urinary tract infections among postmenopausal women [52,53].…”

Section: Management Of Urogenital Symptoms In the Non-breast Cancer Pmentioning

confidence: 99%

Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?

et al. 2008

View full text Add to dashboard Cite

Disclosure:The article discusses Replens (Wellspring Pharmaceutical) as a vaginal lubricant/moisturizer and Estring (Pfizer) and Vagifem (Novo Nordisk) as topical estrogen replacements. W.W. has received an honorarium from Wyeth and Berlex as a guest speaker at CME events. No other potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article. LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Describe the urogenital consequences of antiestrogen treatment among women with a prior diagnosis of breast cancer and the effects that these side effects have on quality of life and medication compliance.2. Advise on the standard treatment of urogenital atrophy, including alternatives to topical estrogen replacement, in the non-breast cancer and breast cancer populations.3. Evaluate the evidence for the current recommendations of estrogen replacement therapy among women with a prior diagnosis of breast cancer.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTBreast cancer survivors represent a unique patient population with a high prevalence of menopausal symptoms. Given the improved longevity of cancer patients, the consequences of menopause have become an increasingly important and challenging management issue. To date, considerable attention has been paid to the management of menopausal vasomotor symptoms and bone health among breast cancer patients. As a result, numerous nonhormonal treatment options have been developed for the management of these issues. The treatment of urogenital symptoms among this population is poorly understood and relatively understudied. Although systemic or topical estrogen replacement is the most effective method for treating hypoestrogenemic urogenital symptoms, women with a prior diagnosis of breast cancer are cautioned from taking exogenous estrogens in order to avoid a potential contribution to recurrent breast cancer risk. This review focuses on the urogenital consequences of estrogen deprivation therapy in breast cancer patients and provides practitioners with a simple guide of current and future strategies for managing these symptoms. The Oncologist 2008;13:222-231

show abstract

“…21 There is reasonable data to suggest that local vaginal estrogen may be more effective than systemic HRT in reducing symptoms of postmenopausal vaginal atrophy (vaginal dryness, pruritis, burning and dyspareunia). 22,23 Despite this, there is a paucity of data examining the effectiveness of local estrogen preparations to treat lower urinary tract symptoms. Cardozo and colleagues 24 treated 110 postmenopausal women with Vagifem twice weekly versus placebo for 3 months.…”

Section: Local Vaginal Estrogenmentioning

confidence: 99%